Ettl, Tobias and Baader, K. and Stiegler, C. and Mueller, M. and Agaimy, A. and Zenk, J. and Kuehnel, T. and Gosau, M. and Zeitler, K. and Schwarz, S. and Brockhoff, G. (2012) Loss of PTEN is associated with elevated EGFR and HER2 expression and worse prognosis in salivary gland cancer. BRITISH JOURNAL OF CANCER, 106 (4). pp. 719-726. ISSN 0007-0920, 1532-1827
Full text not available from this repository. (Request a copy)Abstract
BACKGROUND: Activity of the tumour-suppressor gene PTEN is reduced in different types of cancer and implicates non-responsiveness to targeted therapy. This study evaluates the gene and protein status of PTEN in salivary gland carcinomas. METHODS: A total of 287 carcinomas of the major and minor salivary glands were investigated for phosphatase and tensin homologue located on chromosome 10 (PTEN) deletion and loss of PTEN expression using fluorescence in situ hybridisation (FISH) and immunohistochemistry (IHC), respectively. Results were correlated to clinicopathological parameters, long-term survival, epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 (HER2) (IHC and FISH) status of the tumours. RESULTS: Hemizygous deletions of PTEN were found in 35 out of 232 (15.1%) carcinomas, while homozygous deletions were observed in 17 out of 232 (7.3%) tumours. Phosphatase and tensin homologue located on chromosome 10 deletion was common in certain histological subtypes and especially homozygous deletion was associated with high-grade malignancy, lymph node metastases and unfavourable long-term prognosis (P<0.001). Loss of PTEN expression was present in 59 out of 273 (21.6%) carcinomas and was significantly correlated to genomic PTEN deletion, high-grade malignancy (P<0.001), increased tumour size (P=0.036), lymph node metastases (P=0.007) and worse disease-specific survival (P=0.002). Genomic PTEN deletion, in particular homogenous deletion (P<0.001) predominantly occurred in tumours with increased gene copy number of EGFR (60.0%) and/or amplification of HER2 (63.6%). Loss of PTEN expression was frequently found in tumours overexpressing EGFR (28.6%) and/or HER2 (52.6%). CONCLUSION: PTEN function is reduced in different types of salivary gland cancer indicating unfavourable prognosis. Its association with EGFR and HER2 signalling might affect targeted therapy.
| Item Type: | Article |
|---|---|
| Uncontrolled Keywords: | IN-SITU HYBRIDIZATION; METASTATIC COLORECTAL-CANCER; GENE COPY NUMBER; PROSTATE-CANCER; BREAST-CANCER; POOR-PROGNOSIS; PHASE-II; KINASE INHIBITORS; TUMOR SUPPRESSION; GENOMIC DELETION; salivary gland cancer; PTEN; deletion; prognosis; EGFR HER2 |
| Subjects: | 600 Technology > 610 Medical sciences Medicine |
| Divisions: | Medicine > Lehrstuhl für Frauenheilkunde und Geburtshilfe (Schwerpunkt Frauenheilkunde) Medicine > Lehrstuhl für Hals-Nasen-Ohren-Heilkunde Medicine > Lehrstuhl für Mund-, Kiefer- und Gesichtschirurgie Medicine > Lehrstuhl für Pathologie |
| Depositing User: | Dr. Gernot Deinzer |
| Date Deposited: | 19 May 2020 09:27 |
| Last Modified: | 19 May 2020 09:27 |
| URI: | https://pred.uni-regensburg.de/id/eprint/19231 |
Actions (login required)
 |
View Item |
